Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
16.81
-0.18 (-1.06%)
At close: May 12, 2025, 4:00 PM
16.81
0.00 (0.00%)
After-hours: May 12, 2025, 4:05 PM EDT
Company Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V.
| Country | Switzerland |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 108 |
| CEO | Berndt Axel Modig |
Contact Details
Address: Grafenauweg 8 Zug, 6300 Switzerland | |
| Phone | 31 712036410 |
| Website | pharvaris.com |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $20.00 |
| CIK Code | 0001830487 |
| CUSIP Number | N69605108 |
| ISIN Number | NL00150005Y4 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer and Executive Director |
| David W. Nassif J.D. | Chief Financial Officer, Chief Legal Officer and Corporate Secretary |
| Anna Nijdam M.Sc., R.A. | Head of Strategic Finance and Principal Accounting Officer |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Wim Souverijns Ph.D. | Chief Commercial Officer |
| Maryann Cimino | Director of Corporate Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2025 | 6-K | Report of foreign issuer |
| Apr 7, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Dec 2, 2024 | 144 | Filing |
| Nov 13, 2024 | 6-K | Report of foreign issuer |
| Oct 31, 2024 | 144 | Filing |
| Oct 24, 2024 | 144 | Filing |
| Sep 25, 2024 | 6-K | Report of foreign issuer |
| Sep 23, 2024 | 6-K | Report of foreign issuer |
| Sep 20, 2024 | 144 | Filing |